Gilles Salles Selected Research

obinutuzumab

1/2022	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
11/2021	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
1/2021	Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
1/2021	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
9/2020	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
1/2020	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
9/2019	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
1/2019	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
10/2018	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
1/2018	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gilles Salles Research Topics

Disease

86	Neoplasms (Cancer) 01/2022 - 02/2003
78	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2022 - 07/2006
78	Lymphoma (Lymphomas) 03/2022 - 01/2002
59	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2002
36	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2022 - 01/2002
27	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022 - 03/2005
21	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2022 - 10/2003
19	Disease Progression 10/2021 - 05/2004
17	Hodgkin Disease (Hodgkin's Disease) 10/2021 - 01/2002
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 08/2022 - 04/2004
13	Infections 01/2020 - 03/2005
11	Neutropenia 12/2021 - 05/2013
10	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2022 - 02/2003
9	Hematologic Neoplasms (Hematological Malignancy) 12/2021 - 06/2005
9	Multiple Myeloma 01/2021 - 07/2004
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2012
8	Anemia 08/2017 - 03/2005
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2017 - 03/2005
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2021 - 10/2014
5	Fatigue 01/2020 - 03/2013
5	Thrombocytopenia (Thrombopenia) 08/2017 - 03/2013
4	Cytokine Release Syndrome 12/2021 - 01/2019
4	Leukemia 12/2018 - 10/2014
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2021 - 03/2013
3	Carcinoma (Carcinomatosis) 01/2021 - 06/2005
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 12/2019 - 11/2014
3	Necrosis 01/2019 - 05/2016
3	Febrile Neutropenia 01/2019 - 06/2015
3	Cytopenia 08/2014 - 06/2002
3	T-Cell Lymphoma (Lymphoma, T Cell) 03/2013 - 12/2006
2	Pruritus (Itching) 01/2022 - 04/2018
2	Hypertension (High Blood Pressure) 01/2022 - 01/2020

Drug/Important Bio-Agent (IBA)

92	Rituximab (Mabthera)FDA Link 08/2022 - 01/2002
20	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
18	Monoclonal AntibodiesIBA 01/2022 - 01/2002
16	obinutuzumabIBA 01/2022 - 05/2012
16	Prednisone (Sone)FDA LinkGeneric 01/2022 - 01/2002
16	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2002
15	Lenalidomide (CC 5013)FDA Link 01/2022 - 12/2010
15	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 01/2002
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2007
14	Pharmaceutical PreparationsIBA 01/2021 - 10/2014
12	ibrutinibIBA 03/2022 - 01/2016
12	Biological ProductsIBA 01/2022 - 03/2005
11	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2019
8	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2022 - 07/2015
8	tisagenlecleucelIBA 01/2022 - 01/2019
8	tafasitamabIBA 01/2022 - 01/2020
8	CytokinesIBA 12/2021 - 05/2004
8	Proteins (Proteins, Gene)FDA Link 06/2021 - 01/2002
7	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022 - 01/2016
7	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2012
6	polatuzumab vedotinIBA 01/2022 - 06/2015
6	Gemcitabine FDA Link 10/2021 - 11/2013
6	AntigensIBA 01/2020 - 01/2002
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 10/2002
5	InterferonsIBA 01/2022 - 10/2006
5	Bendamustine Hydrochloride FDA Link 01/2022 - 08/2016
5	AntibodiesIBA 01/2022 - 07/2016
5	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 07/2013
5	idelalisibIBA 12/2021 - 01/2017
5	Interleukin-10 (Interleukin 10)IBA 04/2010 - 05/2004
4	fludarabineIBA 01/2022 - 09/2017
4	axicabtagene ciloleucelIBA 01/2022 - 11/2020
4	tazemetostatIBA 06/2021 - 01/2020
4	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 12/2010
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020 - 09/2007
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 10/2002
3	Cytotoxins (Cytolysins)IBA 01/2022 - 07/2019
3	copanlisibIBA 01/2022 - 01/2020
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2021 - 10/2016
3	BI 836826IBA 02/2021 - 10/2020
3	Immunoconjugates (Immunoconjugate)IBA 10/2020 - 06/2015
3	Immunomodulating AgentsIBA 01/2020 - 09/2013
3	Inosine Triphosphate (ITP)IBA 12/2019 - 11/2014
3	AnthracyclinesIBA 05/2018 - 11/2015
3	CreatinineIBA 08/2016 - 04/2016
3	Dexamethasone (Maxidex)FDA LinkGeneric 08/2016 - 12/2010
3	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2016 - 12/2009
3	Asparaginase (Elspar)FDA Link 01/2015 - 08/2012
3	Immunoglobulins (Immunoglobulin)IBA 04/2005 - 02/2002
2	Biosimilar PharmaceuticalsIBA 08/2022 - 05/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 04/2009
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2021
2	NVP-BKM120IBA 01/2022 - 12/2017
2	Alkylating AgentsIBA 01/2022 - 01/2017

Therapy/Procedure

79	Therapeutics 01/2022 - 01/2002
50	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
26	Stem Cell Transplantation 03/2022 - 01/2002
8	Transplantation 06/2022 - 04/2006
7	Radiotherapy 10/2022 - 11/2007
7	Hematopoietic Stem Cell Transplantation 01/2020 - 07/2013
6	Salvage Therapy 01/2022 - 01/2002
6	Aftercare (After-Treatment) 01/2020 - 12/2008
6	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2019 - 12/2017
5	Splenectomy 01/2016 - 06/2002
4	Cell Transplantation 12/2017 - 12/2017
3	Autologous Transplantation 08/2019 - 08/2007
3	Ligation 11/2017 - 04/2015
3	Injections 06/2017 - 10/2014